Acrivon Therapeutics, Inc. (ACRV) FinancialsACRVAcrivon Therapeutics, Inc.

Evaluating the bottom line, Acrivon Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -64.63%, provide a clear picture of how effectively ACRV converts its operational activities into shareholder value.

In the context of the broader market, ACRV competes directly with industry leaders such as CPIX and CING. With a market capitalization of $67.27M, it holds a significant position in the sector. When comparing efficiency, ACRV's gross margin of N/A stands against CPIX's 100.00% and CING's N/A. Such benchmarking helps identify whether Acrivon Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Acrivon has reported significant losses, with a net income of -$19,042,000 in Q1 2026 and a gross profit of $0 in Q2 2026. The company has a current ratio of 7.99, indicating good short-term liquidity, but ongoing losses raise concerns about long-term viability.